Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Thursday at a closing price of $7.69, with 2.95 million shares of worth about $22.68 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -2.90% during that period and on March 20, 2025 the price saw a gain of about 0.79%. Currently the company’s common shares owned by public are about 208.54M shares, out of which, 197.24M shares are available for trading.
Stock saw a price change of 1.99% in past 5 days and over the past one month there was a price change of -18.10%. Year-to-date (YTD), BCRX shares are showing a performance of 2.26% which increased to 51.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.03 but also hit the highest price of $9.50 during that period. The average intraday trading volume for Biocryst Pharmaceuticals Inc shares is 3.13 million. The stock is currently trading -4.02% below its 20-day simple moving average (SMA20), while that difference is down -5.18% for SMA50 and it goes to 1.08% higher than SMA200.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) currently have 208.54M outstanding shares and institutions hold larger chunk of about 78.44% of that.
The stock has a current market capitalization of $1.61B and its 3Y-monthly beta is at 1.75. It has posted earnings per share of -$0.43 in the same period. It has Quick Ratio of 2.58. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCRX, volatility over the week remained 2.96% while standing at 4.78% over the month.
Stock’s fiscal year EPS is expected to rise by 83.02% while it is estimated to increase by 410.96% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wedbush on February 25, 2025 offering an Outperform rating for the stock and assigned a target price of $15 to it. Coverage by JP Morgan stated Biocryst Pharmaceuticals Inc (BCRX) stock as an Overweight in their note to investors on November 20, 2023, suggesting a price target of $10 for the stock. On September 18, 2023, RBC Capital Mkts Upgrade their recommendations, while on August 04, 2023, Jefferies Upgrade their ratings for the stock with a price target of $11. Stock get a Buy rating from BofA Securities on July 13, 2023.
